Tempus AI (TEM) said Wednesday its US Food and Drug Administration-approved next-generation sequencing test xT CDx for solid tumor profiling is now available nationwide.
Using a normal-matched approach, where a solid tumor and a normal patient sample are sequenced in parallel, xT CDx can more accurately detect cancer-driving somatic variants, the company said.
All orders for tumor + normal match tests, previously conducted through the company's xT assay, will transition to xT CDx without changing the current ordering workflow, it added.
The company's shares were up 8.9% in recent trading.
Price: 34.67, Change: +2.84, Percent Change: +8.91
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。